


## Data Sheet

<b>Product Name:</b>	OG-L002
<b>Cat. No.:</b>	CS-0015247
<b>CAS No.:</b>	1357302-64-7
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>15</sub> NO
<b>Molecular Weight:</b>	225.29
<b>Target:</b>	Histone Demethylase; HSV; Monoamine Oxidase
<b>Pathway:</b>	Anti-infection; Epigenetics; Neuronal Signaling
<b>Solubility:</b>	DMSO : 250 mg/mL (1109.68 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

OG-L002 is a potent and highly selective **LSD1** inhibitor with an **IC<sub>50</sub>** of 0.02  $\mu$ M. OG-L002 is a potent **monoamine oxidases (MAO)** inhibitor with **IC<sub>50</sub>s** of 1.38  $\mu$ M and 0.72  $\mu$ M for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of **HSV IE** genes<sup>[1]</sup>. **IC<sub>50</sub> & Target:** IC<sub>50</sub>: 0.02  $\mu$ M (LSD1), 1.38  $\mu$ M (MAO-A), 0.72  $\mu$ M (MAO-B), HSV IE<sup>[1]</sup> *In Vitro:* OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC<sub>50</sub> (IC<sub>50</sub>: ~10  $\mu$ M in HeLa cells; IC<sub>50</sub>: ~3  $\mu$ M in HFF cells) relative to the control MAOI TCP (IC<sub>50</sub>: ~1 mM)<sup>[1]</sup>. *In Vivo:* OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection<sup>[1]</sup>.

### References:

[1]. Liang Y, et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio. 2013 Feb 5;4(1):e00558-12.

### CAIndexNames:

[1,1'-Biphenyl]-3-ol, 4'-[(1R,2S)-2-aminocyclopropyl]-

### SMILES:

OC1=CC(C2=CC=C([C@@H]3[C@@H](N)C3)C=C2)=CC=C1

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA